We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$58.5M
Cap. Flow
+$123M
Cap. Flow %
7.76%
Top 10 Hldgs %
54.43%
Holding
78
New
26
Increased
17
Reduced
7
Closed
12

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$50.8M
2
ELAN icon
Elanco Animal Health
ELAN
+$41.9M
3
KVUE icon
Kenvue
KVUE
+$41.7M
4
SNY icon
Sanofi
SNY
+$37.1M
5
MRK icon
Merck
MRK
+$21.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$51.1M
2
EXEL icon
Exelixis
EXEL
+$36.2M
3
BSX icon
Boston Scientific
BSX
+$32.9M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$32.9M
5
AZN icon
AstraZeneca
AZN
+$22.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.19%
2 Miscellaneous 11.53%
3 Consumer Staples 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$234M 14.73%
1,381,149
– –
NTRA icon
2
Natera
NTRA
$47.6B
$137M 8.65%
3,100,560
– –
AZN icon
3
AstraZeneca
AZN
$243B
$92.3M 5.82%
681,418
-167,341
-20% -$22.9M
MRK icon
4
Merck
MRK
$364B
$75M 4.73%
728,404
+201,031
+38% +$21.7M
ASND icon
5
Ascendis Pharma A/S
ASND
$17.1B
$70.6M 4.45%
754,032
– –
RYZB
6
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$53.7M 3.39%
+2,419,528
New +$50.8M
DXCM icon
7
DexCom
DXCM
$31.7B
$51.3M 3.24%
550,197
+179,477
+48% +$20.2M
JBIO
8
Jade Biosciences
JBIO
$1.21B
$51M 3.22%
107,391
– –
ISRG icon
9
Intuitive Surgical
ISRG
$125B
$50.6M 3.19%
173,277
-27,905
-14% -$8.71M
VERA icon
10
Vera Therapeutics
VERA
$2.43B
$47.5M 3%
3,467,156
– –
ELAN icon
11
Elanco Animal Health
ELAN
$11.8B
$40.6M 2.56%
+3,610,024
New +$41.9M
IWM icon
12
PUT
iShares Russell 2000 ETF
IWM
$79B
$39.8M 2.51%
+225,000
New +$42.2M
ARGX icon
13
argenx
ARGX
$62.7B
$38.4M 2.42%
78,186
+38,265
+96% +$18.7M
IMTX icon
14
Immatics
IMTX
$1.39B
$37.7M 2.38%
3,251,509
+210,022
+7% +$2.51M
SNY icon
15
Sanofi
SNY
$103B
$37.3M 2.35%
+695,375
New +$37.1M
KVUE icon
16
Kenvue
KVUE
$34.1B
$36.2M 2.28%
+1,802,084
New +$41.7M
IDXX icon
17
Idexx Laboratories
IDXX
$40.6B
$34.1M 2.15%
77,881
+7,207
+10% +$3.59M
IMGN
18
DELISTED
Immunogen Inc
IMGN
$32.5M 2.05%
2,045,202
+1,217,884
+147% +$20.3M
CYTK icon
19
Cytokinetics
CYTK
$10.3B
$31.2M 1.97%
1,060,164
+216,936
+26% +$7.22M
IDYA icon
20
IDEAYA Biosciences
IDYA
$3.7B
$28M 1.77%
1,037,187
+372,441
+56% +$9.44M
ZNTL icon
21
Zentalis Pharmaceuticals
ZNTL
$360M
$24.3M 1.53%
1,211,641
+383,636
+46% +$9.74M
SPY icon
22
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
$21.4M 1.35%
+50,000
New +$22.2M
EXEL icon
23
PUT
Exelixis
EXEL
$14.5B
$19.9M 1.26%
+912,600
New +$19.1M
EXEL icon
24
Exelixis
EXEL
$14.5B
$18.2M 1.15%
830,764
-1,729,974
-68% -$36.2M
INZY
25
DELISTED
Inozyme Pharma
INZY
$18M 1.13%
4,280,308
+625,000
+17% +$3.18M
1
2 3 4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q3 2023 Portfolio in Review

As of Q3 2023, Sofinnova Investments held 78 positions worth $1.59B, up 3.8% from $1.53B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sofinnova Investments deployed $123M of net new capital in Q3 2023, opening 26 new positions and adding to 17 existing holdings. Its largest new stake was RayzeBio, Inc. Common Stock: 2,419,528 shares worth $53.7M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Exelixis, an estimated $36.2M trimmed.

  • Sofinnova Investments's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 2,419,528 shares worth $53.7M.
  • Sofinnova Investments added most to Merck in Q3 2023, an estimated $21.7M increase.
  • Sofinnova Investments's biggest Q3 2023 reduction was Exelixis, cutting an estimated $36.2M.
  • Sofinnova Investments fully exited Vertex Pharmaceuticals in Q3 2023, selling an estimated $51.1M.
  • Sofinnova Investments's ten largest holdings make up 54% of its $1.59B portfolio in Q3 2023.
  • Sofinnova Investments opened 26 new positions and closed 12 in Q3 2023.
  • Sofinnova Investments's portfolio value rose 3.8% quarter-over-quarter to $1.59B.

Based on Sofinnova Investments's 13F filing for Q3 2023, filed 14 Nov 2023.